Get the Stockscreener App
2.41
13.15%
0.28
Pre-market:
2.40
-0.01
-0.41%
Nrx Pharmaceuticals Inc stock is traded at $2.41, with a volume of 2.58M.
It is up +13.15% in the last 24 hours and up +26.18% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.13
Open:
$2.135
24h Volume:
2.58M
Relative Volume:
2.58
Market Cap:
$76.81M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-1.5352
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
+26.84%
1M Performance:
+26.18%
6M Performance:
-17.18%
1Y Performance:
+19.90%
1-Day Range:
$2.12
$2.49
1-Week Range:
$1.72
$2.49
52-Week Range:
$1.58
$3.84
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.41 | 67.89M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals, Inc. (NRXP) surpasses Q4 earnings estimates - MSN
NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101 - Insider Monkey
NRx says FDA will review NRX-100 without new trials - MSN
Nrx Pharmaceuticals: Extensive Clinical, Regulatory, and Financial Risks Make Shares Highly Speculative - TipRanks
5 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
NRx Pharmaceuticals, Inc. 8-K Filing Details: Company Information, Stock, and Warrants Registered on NASDAQ – March 2026 - Minichart
NRx Pharmaceuticals Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress - Investing News Network
NRx Pharmaceuticals Stockholders Approve Incentive Plan Amendment - TipRanks
NRx Pharmaceuticals stock rating reiterated at Buy by BTIG on FDA progress - Investing.com Australia
NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate - Stock Titan
NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
NRx Says FDA Finds No Bioequivalence Issues in Ketamine Filing - MyChesCo
NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from BTIG Research - MarketBeat
NRx Pharmaceuticals (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress - The Globe and Mail
NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Beats Expectations By $0.28 EPS - MarketBeat
NRx Pharmaceuticals Announces Full-Year 2025 Results with Commercial and Regulatory Updates - citybiz
NRX Pharmaceuticals’ 2025 Q4 Earnings Call: Shifting Commercialization Strategy and NDA Timeline Clash With Prior Statements - Bitget
Earnings call transcript: NRX Pharmaceuticals Q4 2025 shows operational strides By Investing.com - Investing.com India
NRXP: Reduced losses, revenue growth, and key drug milestones position for profitability in 2026 - TradingView
NRx Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: NRX Pharmaceuticals Q4 2025 shows operational strides - Investing.com
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress - marketscreener.com
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
NRx says it can fund operations through 2026 as ketamine review advances - Stock Titan
NRx Says FDA Will Review NRX-100 Without New Trials - MyChesCo
NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead - Yahoo Finance
NRX Pharmaceuticals, Inc. 2025 Annual Report: Financials, Risk Factors, and Nasdaq Listing Overview - Minichart
NRXP: Analyst Jason Kolbert Maintains 'Buy' Rating and $34 PT | - GuruFocus
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates - Yahoo Finance
NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000KNRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NRx Pharmaceuticals (NRXP) details ketamine NDA plans, HOPE TMS clinic growth, and financings - Stock Titan
NRXP: All proposals passed, marking a pivotal year of clinical revenue and strategic progress - TradingView
NRx Pharmaceuticals, Inc. (NRXP) Exceeds Expectations for Q4 Earnings - Bitget
If You Invested $1,000 in Nrx Pharmaceuticals Inc (NRXP) - Stock Titan
Sentiment Watch: What is the dividend yield of NRx Pharmaceuticals Inc2026 Highlights & Reliable Volume Spike Alerts - baoquankhu1.vn
NRX Pharmaceuticals Inc expected to post breakeven results a shareEarnings Preview - TradingView
NRx Pharmaceuticals, Inc. to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 - Investing News Network
NRx Pharmaceuticals (NASDAQ: NRXP) Schedules March 24 Conference Call To Review 2025 Results, Clinical Progress - Digital Journal
Nrx Pharmaceuticals, Inc. (Nasdaq NRXP) to report full year 2025 financial results and provide a corporate update on March 24, 2026 - marketscreener.com
NRx Pharmaceuticals to Host Conference Call on March 24, 2026, to Discuss Financial Results and Drug Development Progress - Quiver Quantitative
NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History - Yahoo Finance
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 - ChartMill
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product - Digital Journal
D Boral Capital maintains NRx Pharmaceuticals (NRXP) buy recommendation - MSN
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Airsculpt Technologies (AIRS) and NRX Pharmaceuticals (NRXP) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Stoke Therapeutics (STOK), NRX Pharmaceuticals (NRXP) and Airsculpt Technologies (AIRS) - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals receives FDA bioequivalence approval notice By Investing.com - Investing.com South Africa
Joseph Michael Casper Net Worth (2026) - GuruFocus
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):